Effect of mTORC1/mTORC2 inhibition on T cell function: Potential role in graft-versus-host disease control

British Journal of Haematology

Volumn 173, Issue 5, 2016, Pages 754-768

  Herrero Sánchez, Ma Carmen ^a,b,c   Rodríguez Serrano, Concepción ^a,b,c   Almeida, Julia ^b,c   San Segundo, Laura ^b,c   Inogés, Susana ^d   Santos Briz, Ángel ^a,b   García Briñón, Jesús ^b,e   Sanmiguel, Jesús F ^d   Del Cañizo, Consuelo ^a,b,c   Blanco, Belén ^a,b  

^a HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^b INSTITUTO DE INVESTIGACIÓN BIOMÉDICA DE SALAMANCA IBSAL   (Spain)

^c Centro de Investigacion del Cancer   (Spain)

^d UNIVERSITY CLINIC OF NAVARRA   (Spain)

^e UNIVERSITY OF SALAMANCA   (Spain)

Author keywords

Graft versus host disease; mTOR inhibitors; T cell

Indexed keywords

CC 214 1; CC 214 2; GAMMA INTERFERON; GRANZYME B; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; RAPAMYCIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; 6-(4-(1H-1,2,4-TRIAZOL-3-YL)PHENYL)-1-(2-(TETRAHYDRO-2H-PYRAN-4-YL)ETHYL)-1H-IMIDAZO(4,5-B)PYRAZIN-2(3H)-ONE; CC214-2; IMIDAZOLE DERIVATIVE; MECHANISTIC TARGET OF RAPAMYCIN COMPLEX 1; MULTIPROTEIN COMPLEX; PYRAZINE DERIVATIVE; TARGET OF RAPAMYCIN KINASE; TOR COMPLEX 2;

ACUTE GRAFT VERSUS HOST DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CHEMOPROPHYLAXIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG POTENCY; DRUG TARGETING; FEMALE; HUMAN; HUMAN CELL; IMMUNOLOGICAL TOLERANCE; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE FUNCTION; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TH1 CELL; TH2 CELL; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; C57BL MOUSE; CELL CULTURE; DRUG EFFECTS; GRAFT VS HOST DISEASE; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; MALE;

ANIMALS; CELLS, CULTURED; FEMALE; GRAFT VS HOST DISEASE; HUMANS; IMIDAZOLES; IMMUNE TOLERANCE; LYMPHOCYTE ACTIVATION; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MULTIPROTEIN COMPLEXES; PYRAZINES; T-LYMPHOCYTES; TOR SERINE-THREONINE KINASES;

EID: 84959432074     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.13984     Document Type: Article

References (56)

1. Abouelnasr, A., Roy, J., Cohen, S., Kiss, T. & Lachance, S. (2013) Defining the role of sirolimus in the management of graft-versus-host disease: from prophylaxis to treatment. Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation, 19, 12-21.
2. Alam, A., Cohen, L.Y., Aouad, S. & Sekaly, R.P. (1999) Early activation of caspases during T lymphocyte stimulation results in selective substrate cleavage in nonapoptotic cells. The Journal of Experimental Medicine, 190, 1879-1890.
3. Algarte, M., Lecine, P., Costello, R., Plet, A., Olive, D. & Imbert, J. (1995) In vivo regulation of interleukin-2 receptor alpha gene transcription by the coordinated binding of constitutive and inducible factors in human primary T cells. The EMBO Journal, 14, 5060-5072.
4. Amarnath, S., Flomerfelt, F.A., Costanzo, C.M., Foley, J.E., Mariotti, J., Konecki, D.M., Gangopadhyay, A., Eckhaus, M., Wong, S., Levine, B.L., June, C.H. & Fowler, D.H. (2010) Rapamycin generates anti-apoptotic human Th1/Tc1 cells via autophagy for induction of xenogeneic GVHD. Autophagy, 6, 523-541.
5. Araki, K., Turner, A.P., Shaffer, V.O., Gangappa, S., Keller, S.A., Bachmann, M.F., Larsen, C.P. & Ahmed, R. (2009) mTOR regulates memory CD8 T-cell differentiation. Nature, 460, 108-112.
6. Barnhart, B.C., Lam, J.C., Young, R.M., Houghton, P.J., Keith, B. & Simon, M.C. (2008) Effects of 4E-BP1 expression on hypoxic cell cycle inhibition and tumor cell proliferation and survival. Cancer Biology & Therapy, 7, 1441-1449.
7. Blazar, B.R., Taylor, P.A., Panoskaltsis-Mortari, A. & Vallera, D.A. (1998) Rapamycin inhibits the generation of graft-versus-host disease- and graft-versus-leukemia-causing T cells by interfering with the production of Th1 or Th1 cytotoxic cytokines. The Journal of Immunology, 160, 5355-5365.
8. van Burik, J.A., Carter, S.L., Freifeld, A.G., High, K.P., Godder, K.T., Papanicolaou, G.A., Mendizabal, A.M., Wagner, J.E., Yanovich, S. & Kernan, N.A. (2007) Higher risk of cytomegalovirus and aspergillus infections in recipients of T cell-depleted unrelated bone marrow: analysis of infectious complications in patients treated with T cell depletion versus immunosuppressive therapy to prevent graft-versus-host disease. Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation, 13, 1487-1498.
9. Carracedo, A., Ma, L., Teruya-Feldstein, J., Rojo, F., Salmena, L., Alimonti, A., Egia, A., Sasaki, A.T., Thomas, G., Kozma, S.C., Papa, A., Nardella, C., Cantley, L.C., Baselga, J. & Pandolfi, P.P. (2008) Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. The Journal of Clinical Investigation, 118, 3065-3074.
10. Chen, S., Liu, D., Wu, J., Xu, B., Lu, K., Zhu, W. & Chen, M. (2014a) Effect of inhibiting the signal of mammalian target of rapamycin on memory T cells. Transplantation Proceedings, 46, 1642-1648.
11. Chen, X., Diaz-Rodriguez, E., Ocio, E.M., Paiva, B., Mortensen, D.S., Lopez-Girona, A., Chopra, R., Miguel, J.S. & Pandiella, A. (2014b) Genetic and pharmacologic evidence that mTOR targeting outweighs mTORC1 inhibition as an antimyeloma strategy. Molecular Cancer Therapeutics, 13, 504-516.
12. Choo, A.Y., Yoon, S.O., Kim, S.G., Roux, P.P. & Blenis, J. (2008) Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation. Proceedings of the National Academy of Sciences of the United States of America, 105, 17414-17419.
13. Cooke, K.R., Kobzik, L., Martin, T.R., Brewer, J., Delmonte, Jr, J., Crawford, J.M. & Ferrara, J.L. (1996) An experimental model of idiopathic pneumonia syndrome after bone marrow transplantation: I. The roles of minor H antigens and endotoxin. Blood, 88, 3230-3239.
14. Cullis, B., D'Souza, R., McCullagh, P., Harries, S., Nicholls, A., Lee, R. & Bingham, C. (2006) Sirolimus-induced remission of posttransplantation lymphoproliferative disorder. American Journal of Kidney Diseases: The Official Journal of the National Kidney Foundation, 47, e67-e72.
15. Delgoffe, G.M., Pollizzi, K.N., Waickman, A.T., Heikamp, E., Meyers, D.J., Horton, M.R., Xiao, B., Worley, P.F. & Powell, J.D. (2011) The kinase mTOR regulates the differentiation of helper T cells through the selective activation of signaling by mTORC1 and mTORC2. Nature Immunology, 12, 295-303.
16. Demosthenous, C., Han, J.J., Stenson, M.J., Maurer, M.J., Wellik, L.E., Link, B., Hege, K., Dogan, A., Sotomayor, E., Witzig, T. & Gupta, M. (2015) Translation initiation complex eIF4F is a therapeutic target for dual mTOR kinase inhibitors in non-Hodgkin lymphoma. Oncotarget, 6, 9488-9501.
17. Feldman, M.E., Apsel, B., Uotila, A., Loewith, R., Knight, Z.A., Ruggero, D. & Shokat, K.M. (2009) Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biology, 7, e38.
18. Ferreira, H., Bustorff, M., Santos, J., Ferreira, I., Sampaio, S., Salome, I., Bastos, J., Bergantim, R., Principe, F. & Pestana, M. (2015) Post-transplant lymphoproliferative disorder: a single-center experience. Transplantation Proceedings, 47, 981-984.
19. Furukawa, S., Wei, L., Krams, S.M., Esquivel, C.O. & Martinez, O.M. (2013) PI3Kdelta inhibition augments the efficacy of rapamycin in suppressing proliferation of Epstein-Barr virus (EBV)+ B cell lymphomas. American Journal of Transplantation: Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 13, 2035-2043.
20. Gan, X., Wang, J., Su, B. & Wu, D. (2011) Evidence for direct activation of mTORC2 kinase activity by phosphatidylinositol 3, 4, 5-trisphosphate. The Journal of Biological Chemistry, 286, 10998-11002.
21. Gini, B., Zanca, C., Guo, D., Matsutani, T., Masui, K., Ikegami, S., Yang, H., Nathanson, D., Villa, G.R., Shackelford, D., Zhu, S., Tanaka, K., Babic, I., Akhavan, D., Lin, K., Assuncao, A., Gu, Y., Bonetti, B., Mortensen, D.S., Xu, S., Raymon, H.K., Cavenee, W.K., Furnari, F.B., James, C.D., Kroemer, G., Heath, J.R., Hege, K., Chopra, R., Cloughesy, T.F. & Mischel, P.S. (2013) The mTOR kinase inhibitors, CC214-1 and CC214-2, preferentially block the growth of EGFRvIII-activated glioblastomas. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 19, 5722-5732.
22. Glimcher, L.H., Townsend, M.J., Sullivan, B.M. & Lord, G.M. (2004) Recent developments in the transcriptional regulation of cytolytic effector cells. Nature Reviews Immunology, 4, 900-911.
23. Hess, A.D. (2006) Modulation of graft-versus-host disease: role of regulatory T lymphocytes. Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation, 12, 13-21.
24. Juchem, K.W., Anderson, B.E., Zhang, C., McNiff, J.M., Demetris, A.J., Farber, D.L., Caton, A.J., Shlomchik, W.D. & Shlomchik, M.J. (2011) A repertoire-independent and cell-intrinsic defect in murine GVHD induction by effector memory T cells. Blood, 118, 6209-6219.
25. Julien, L.A., Carriere, A., Moreau, J. & Roux, P.P. (2010) mTORC1-activated S6K1 phosphorylates Rictor on threonine 1135 and regulates mTORC2 signaling. Molecular and Cellular Biology, 30, 908-921.
26. Kaplan, B., Qazi, Y. & Wellen, J.R. (2014) Strategies for the management of adverse events associated with mTOR inhibitors. Transplant Reviews (Orlando), 28, 126-133.
27. Lee, K., Gudapati, P., Dragovic, S., Spencer, C., Joyce, S., Killeen, N., Magnuson, M.A. & Boothby, M. (2010) Mammalian target of rapamycin protein complex 2 regulates differentiation of Th1 and Th2 cell subsets via distinct signaling pathways. Immunity, 32, 743-753.
28. Li, Y., Li, X.C., Zheng, X.X., Wells, A.D., Turka, L.A. & Strom, T.B. (1999) Blocking both signal 1 and signal 2 of T-cell activation prevents apoptosis of alloreactive T cells and induction of peripheral allograft tolerance. Nature Medicine, 5, 1298-1302.
29. Makrigiannis, A.P. & Hoskin, D.W. (1997) Inhibition of CTL induction by rapamycin: IL-2 rescues granzyme B and perforin expression but only partially restores cytotoxic activity. The Journal Immunology, 159, 4700-4707.
30. Manning, B.D. & Cantley, L.C. (2007) AKT/PKB signaling: navigating downstream. Cell, 129, 1261-1274.
31. Mariotti, J., Foley, J., Jung, U., Borenstein, T., Kantardzic, N., Han, S., Hanson, J.T., Wong, E., Buxhoeveden, N., Trepel, J.B., Fojo, A.T., Telford, W. & Fowler, D.H. (2008) Ex vivo rapamycin generates apoptosis-resistant donor Th2 cells that persist in vivo and prevent hemopoietic stem cell graft rejection. The Journal Immunology, 180, 89-105.
32. Marty, F.M., Bryar, J., Browne, S.K., Schwarzberg, T., Ho, V.T., Bassett, I.V., Koreth, J., Alyea, E.P., Soiffer, R.J., Cutler, C.S., Antin, J.H. & Baden, L.R. (2007) Sirolimus-based graft-versus-host disease prophylaxis protects against cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation: a cohort analysis. Blood, 110, 490-500.
33. Mortensen, D.S., Sapienza, J., Lee, B.G., Perrin-Ninkovic, S.M., Harris, R., Shevlin, G., Parnes, J.S., Whitefield, B., Hickman, M., Khambatta, G., Bisonette, R.R., Peng, S., Gamez, J.C., Leisten, J., Narla, R.K., Fultz, K.E. & Sankar, S. (2013) Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. Bioorganic & Medicinal Chemistry Letters, 23, 1588-1591.
34. Nikolaeva, N., Bemelman, F.J., Yong, S.L., van Lier, R.A. & ten Berge, I.J. (2006) Rapamycin does not induce anergy but inhibits expansion and differentiation of alloreactive human T cells. Transplantation, 81, 445-454.
35. Nosrati, N., Kapoor, N.R. & Kumar, V. (2014) Combinatorial action of transcription factors orchestrates cell cycle-dependent expression of the ribosomal protein genes and ribosome biogenesis. The FEBS Journal, 281, 2339-2352.
36. + T-cell differentiation. International Immunology, 22, 619-625.
37. Pascual, J. (2007) Post-transplant lymphoproliferative disorder-the potential of proliferation signal inhibitors. Nephrology, Dialysis, Transplantation: Official Publication of the European Dialysis and Transplant Association - European Renal Association, 22(Suppl. 1), i27-i35.
38. + T cell function by the transcription factor Eomesodermin. Science, 302, 1041-1043.
39. Perez-Simón, J.A., Martino, R., Parody, R., Cabrero, M., Lopez-Corral, L., Valcarcel, D., Martinez, C., Solano, C., Vazquez, L., Marquez-Malaver, F.J., Sierra, J. & Caballero, D. (2013) The combination of sirolimus plus tacrolimus improves outcome after reduced-intensity conditioning, unrelated donor hematopoietic stem cell transplantation compared with cyclosporine plus mycofenolate. Haematologica, 98, 526-532.
40. Powell, J.D., Lerner, C.G. & Schwartz, R.H. (1999) Inhibition of cell cycle progression by rapamycin induces T cell clonal anergy even in the presence of costimulation. The Journal Immunology, 162, 2775-2784.
41. + T cell fate by regulating the expression of transcription factors T-bet and Eomesodermin. Immunity, 32, 67-78.
42. Rodrik-Outmezguine, V.S., Chandarlapaty, S., Pagano, N.C., Poulikakos, P.I., Scaltriti, M., Moskatel, E., Baselga, J., Guichard, S. & Rosen, N. (2011) mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling. Cancer Discovery, 1, 248-259.
43. Sarbassov, D.D., Guertin, D.A., Ali, S.M. & Sabatini, D.M. (2005) Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science, 307, 1098-1101.
44. Sarbassov, D.D., Ali, S.M., Sengupta, S., Sheen, J.H., Hsu, P.P., Bagley, A.F., Markhard, A.L. & Sabatini, D.M. (2006) Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Molecular Cell, 22, 159-168.
45. + T cells correlates with p27kip1 down-regulation and bcl-xL induction, and is prevented by an inhibitor of phosphoinositide 3-kinase activity. The Journal of Biological Chemistry, 279, 910-919.
46. Sparks, C.A. & Guertin, D.A. (2010) Targeting mTOR: prospects for mTOR complex 2 inhibitors in cancer therapy. Oncogene, 29, 3733-3744.
47. Sun, S.Y., Rosenberg, L.M., Wang, X., Zhou, Z., Yue, P., Fu, H. & Khuri, F.R. (2005) Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Research, 65, 7052-7058.
48. Thoreen, C.C., Kang, S.A., Chang, J.W., Liu, Q., Zhang, J., Gao, Y., Reichling, L.J., Sim, T., Sabatini, D.M. & Gray, N.S. (2009) An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. The Journal of Biological Chemistry, 284, 8023-8032.
49. Tomasoni, R., Basso, V., Pilipow, K., Sitia, G., Saccani, S., Agresti, A., Mietton, F., Natoli, G., Colombetti, S. & Mondino, A. (2011) Rapamycin-sensitive signals control TCR/CD28-driven Ifng, Il4 and Foxp3 transcription and promoter region methylation. European Journal of Immunology, 41, 2086-2096.
50. + T cells reflecting their function: inverse correlation between quantitative expression of CD27 and cytotoxic effector function. European Journal of Immunology, 34, 999-1010.
51. + T-cell responses to vaccinia virus vaccination in rhesus macaques. American Journal of Transplantation: Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 11, 613-618.
52. Waickman, A.T. & Powell, J.D. (2012) Mammalian target of rapamycin integrates diverse inputs to guide the outcome of antigen recognition in T cells. The Journal of Immunology, 188, 4721-4729.
53. Wan, X., Harkavy, B., Shen, N., Grohar, P. & Helman, L.J. (2007) Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. Oncogene, 26, 1932-1940.
54. Wang, Y., Yu, Q., He, X., Romigh, T., Altemus, J. & Eng, C. (2014) Activation of AR sensitizes breast carcinomas to NVP-BEZ235's therapeutic effect mediated by PTEN and KLLN upregulation. Molecular Cancer Therapeutics, 13, 517-527.
55. Wullschleger, S., Loewith, R. & Hall, M.N. (2006) TOR signaling in growth and metabolism. Cell, 124, 471-484.
56. Zhou, H.Y. & Huang, S.L. (2012) Current development of the second generation of mTOR inhibitors as anticancer agents. Chinese Journal of Cancer, 31, 8-18.